EPALRESTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H13NO3S2
Molecular Weight	319.399
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O

InChI

InChIKey=CHNUOJQWGUIOLD-NFZZJPOKSA-N

InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

HIDE SMILES / InChI

Molecular Formula	C15H13NO3S2
Molecular Weight	319.399
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	2
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18447661

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Aldose reductase 45 Target ID: P15121 Gene ID: 231.0 Gene Symbol: AKR1B1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/18447661	Inhibitor 8504		0.28 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Diabetic neuropathy 23 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18447661	Primary		Approved 8583	KINEDAK Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
3.9 μg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18447661/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		EPALRESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6.4 μg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18447661/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		EPALRESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
9.9% REVIEW https://pubmed.ncbi.nlm.nih.gov/18447661/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		EPALRESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
50 mg 3 times / day multiple, oral Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	Disc. AE: Thrombocytopenia, unspecified, Jaundice, unspecified, not of newborn... AEs leading to discontinuation/dose reduction: Thrombocytopenia, unspecified (serious) Jaundice, unspecified, not of newborn (serious) Hepatic failure (serious) Acute fulminant hepatitis (serious) Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/

AEs

AE	Significance	Dose	Population
Acute fulminant hepatitis	serious Disc. AE	50 mg 3 times / day multiple, oral Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/
Hepatic failure	serious Disc. AE	50 mg 3 times / day multiple, oral Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/
Jaundice, unspecified, not of newborn	serious Disc. AE	50 mg 3 times / day multiple, oral Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/
Thrombocytopenia, unspecified	serious Disc. AE	50 mg 3 times / day multiple, oral Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18447661/

PubMed

Title	Date	PubMed
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.	2011-08-15	21640744
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy.	2001-06	11353731
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.	1998-06	9628756

Patents

Sample Use Guides

In Vivo Use Guide

50 mg, 3 times/day

Route of Administration: Oral

In Vitro Use Guide

Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:29:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:29:46 GMT 2025`
Record UNII	424DV0807X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KINEDAK

Preferred Name

English

EPALRESTAT

Official Name

English

ALDONIL

Brand Name

English

5-((Z,E)-.BETA.-METHYLCINNAMYLIDENE)-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID

Systematic Name

English

EPALRESTAT [JAN]

Common Name

English

epalrestat [INN]

Common Name

English

Epalrestat [WHO-DD]

Common Name

English

EPALRESTAT [MART.]

Common Name

English

EPALRESTAT [MI]

Common Name

English

ALDORIN

Brand Name

English

TANGLIN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C72880